化学
结直肠癌
免疫系统
壳聚糖
癌症研究
佐剂
药理学
癌症
口服
辅助治疗
钙
胃肠道癌
海藻酸钙
生存素
核酸
免疫疗法
粘液
光动力疗法
胃肠上皮
免疫
葡萄糖醛酸
炎症性肠病
特加福
联合疗法
前药
寡核苷酸
医学
光敏剂
肿瘤微环境
毒品携带者
结肠炎
免疫增强剂
作者
Yuhong Lin,Meiyi Xin,Yang Song,Zhigang Wei,Linna Fan,Yu Zheng,Pornchai Rojsitthisak,Ocean Y. H. Cheung,Jingsheng Hua,Kai Zhao,Yaqiong Zhang
标识
DOI:10.1021/acs.biomac.6c01667
摘要
Abstract Oral nucleic acid therapy for colorectal cancer is constrained by sequential gastrointestinal barriers and poor tumor accumulation. Herein, a barrier-aware, layer-by-layer oral nanoformulation (AMT@FH/CA NPs) is developed for co-delivery of survivin antisense oligonucleotide (ASO) and manganese ions (Mn2+) to enable combined gene-immune therapy. Core nanoparticles are formed by self-assembly of ASO, tannic acid, and Mn2+, functionalized with folic acid-conjugated quaternized chitosan for mucus penetration and tumor targeting, and then coated with a pH-responsive calcium alginate shell for gastric protection and intestinal release. AMT@FH/CA NPs are stable in gastric conditions and selectively target colonic tumor cells. The released ASO downregulates survivin expression, while Mn2+ serves as an immune adjuvant to activate the STING pathway. In an AOM/DSS colitis-associated colorectal cancer model, oral treatment reduces the tumor burden and enhances systemic immune responses without notable organ toxicity. This multi-functional nanoformulation offers a promising oral platform for nucleic acid-based combination therapy of gastrointestinal malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI